Limitations
death, disability, neurodegenerative diseases
NEURODEGENERATIVE DISEASES
The main limitation of the present study is the lack of health-related outcomes (eg, preventing death and disability, restoring or maintaining health and well-being, improving quality of life because of amyloid PET). Such outcomes are difficult to operationalize given the complexity and duration of AD and other neurodegenerative diseases and often require long-term follow-up, making the assessments expensive and logistically complicated.We acknowledge that the AMYPAD-DPMS sample mostly represents an academic memory clinic population, thus limiting the generalizability of our findings to nonacademic settings. Moreover, as 97% of our sample consisted of White patients, our study results might not be generalizable to different memory clinic populations with diverse race or ethnicity. Finally, in order to assess the study end points, we performed several statistical tests (in which pairwise comparisons were adjusted using Bonferroni correction, when applicable), amplifying the probability of false-positive findings.